Table 1.
Summary of clinical features and laboratory results of the family cluster infected with 2019 novel coronavirus, at presentation
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 7 | ||
|---|---|---|---|---|---|---|---|
| Relationship | Mother of patient 3 | Father of patient 3 | Daughter of patients 1 and 2 | Son-in-law of patients 1 and 2 | Grandson of patients 1 and 2 | Mother of patient 4 in Shenzhen | |
| Age (years) | 65 | 66 | 37 | 36 | 10 | 63 | |
| Sex | Female | Male | Female | Male | Male | Female | |
| Occupation | Retired | Retired | Office worker | Architect | Student | Retired | |
| Chronic medical illness | Hypertension; benign intracranial tumour treated by gamma knife | Hypertension | None | Chronic sinusitis | None | Diabetes | |
| Interval between symptom onset and arrival at Wuhan (days) | 5 (hospital exposure) | 6 | 4 (hospital exposure) | 3 | NA | NA | |
| Interval between admission to hospital and symptom onset (days) | 7 | 6 | 9 | 10 | NA | 7 | |
| Presenting symptoms and signs | .. | .. | .. | .. | .. | .. | |
| Fever | + | + | + | + | − | + | |
| Cough | + (dry) | + (dry) | − | + (productive) | − | + (dry) | |
| Generalised weakness | + | + | − | − | − | + | |
| Nasal congestion | − | − | + | − | − | − | |
| Rhinorrhoea | − | − | − | + | − | − | |
| Sneezing | − | − | − | + | − | − | |
| Sore throat | − | − | + | − | − | − | |
| Pleuritic chest pain | − | − | + | − | − | − | |
| Diarrhoea | − | − | + (3 days, 5–6 times per day) | + (4 days, 7–8 times per day) | − | − | |
| Body temperature (°C) | 39·0 | 39·0 | 36·2 | 36·5 | 36·5 | 39·0 | |
| Oximetry saturation (%) | 94% | 96% | NA | NA | NA | NA | |
| Haemoglobin (g/dL); (male normal range 13·3–17·1; female normal range 11·5–14·8) | 13·1 | 15·6 | 15·0 | 15·2 | 14·6 | 13·0 | |
| White blood cell count (× 109 cells per L); (normal range 3·9–9·9) | 4·8 | 4·2 | 5·6 | 11·4 (↑) | 6·5 | 4·3 | |
| Neutrophil count (× 109 cells per L); (normal range 2·0–7·4) | 4·0 | 3·2 | 3·1 | 8·1 (↑) | 3·2 | 2·7 | |
| Lymphocyte count (× 109 cells per L); (normal range 1·1–3·6) | 0·6 (↓) | 0·7 (↓) | 2·2 | 2·7 | 2·8 | 1·2 | |
| Platelet count (× 109 cells per L); (normal range 162–341) | 157 (↓) | 118 (↓) | 224 | 196 | 197 | 205 | |
| Prothrombin time (s); (normal range 11·0–14·5) | 12·6 | 12·5 | 13·0 | 13·0 | 13·1 | 12·9 | |
| International normalised ratio | 1·0 | 1·0 | 1·0 | 1·0 | 1·0 | 1·0 | |
| Activated partial thromboplastin time (s); (normal range 26·0–40·0) | 45·4 (↑) | 45·3 (↑) | 36·0 | 31·4 | 34·0 | 35·8 | |
| D-dimer (μg/mL); (normal range 0·0–0·5) | 0·6 (↑) | 0·3 | NA | NA | NA | 0·6 (↑) | |
| Fibrinogen (g/dL); (normal range 2·0–4·0) | 6·2 (↑) | 5·1 (↑) | 3·8 | 3·8 | 2·9 | 4·5 (↑) | |
| C-reactive protein (mg/L); (normal range 0·0–5·0) | 55·6 (↑) | 34·2 (↑) | 0·5 | 4·9 | 0·2 | 44·9 (↑) | |
| Albumin (g/L); (normal range 35·0–52·0) | 39·4 | 38·5 | 50·4 | 48·1 | 49·1 | 41·2 | |
| Bilirubin (μmol/L); (normal range 0·0–21·0) | 6·9 | 5·9 | 9·3 | 8·9 | 3·6 | 10·4 | |
| Alkaline phosphatase (U/L); (normal range 35–105) | 68 | 56 | 56 | 48 | 211 (↑) | 66 | |
| Alanine aminotransferase (U/L); (normal range 0·0–33·0) | 14·2 | 13·9 | 25·9 | 20·2 | 23·9 | 17·3 | |
| Aspartate aminotransferase (U/L); (normal range 0·0–32·0) | 20·5 | 23·3 | 27·4 | 18·1 | 28·2 | 27·6 | |
| Urea (mmol/L); (normal range 2·8–8·1) | 3·5 | 5·7 | 3·1 | 5·2 | 5·6 | 4·9 | |
| Creatinine (μmol/L); (normal range 44–80) | 53 | 93 (↑) | 67 | 87 (↑) | 51 | 55 | |
| Sodium (mmol/L); (normal range 136–145) | 136 | 133 (↓) | 142 | 141 | 141 | 139 | |
| Potassium (mmol/L); (normal range 3·5–5·1) | 3·2 (↓) | 3·7 | 3·7 | 3·7 | 3·9 | 3·8 | |
| Creatine kinase (U/L); (normal range 0–170) | 42 | 109 | 50 | 137 | 78 | 143 | |
| Lactate dehydrogenase (U/L); (normal range 135–214) | 286 (↑) | 232 (↑) | 192 | 176 | 194 | 252 (↑) | |
| Amylase (U/L); (normal range 28–100) | NA | NA | 70 | 61 | 61 | NA | |
NA=not available. +=positive. –=negative. ↑=above normal range. ↓=below normal range.